The patient’s symptoms suggest that they may be suffering from haemolytic uraemic syndrome (HUS), which is often caused by an infection with E.coli 0157:H7.

HUS is characterized by a combination of haemolytic anaemia, thrombocytopaenia, and acute kidney injury, which can ultimately lead to renal failure.

The presence of bloody diarrhoea in the patient’s medical history is a significant indicator of HUS. Additionally, the reduced urine output is likely due to the acute kidney injury, while the bruising may be a result of the thrombocytopaenia associated with HUS.

Understanding Haemolytic Uraemic Syndrome

Haemolytic uraemic syndrome (HUS) is a condition that primarily affects young children and is characterized by a triad of symptoms, including acute kidney injury, microangiopathic haemolytic anaemia, and thrombocytopenia. The most common cause of HUS in children is Shiga toxin-producing Escherichia coli (STEC) 0157:H7, which accounts for over 90% of cases. Other causes of HUS include pneumococcal infection, HIV, systemic lupus erythematosus, drugs, and cancer.

To diagnose HUS, doctors may perform a full blood count, check for evidence of STEC infection in stool culture, and conduct PCR for Shiga toxins. Treatment for HUS is supportive and may include fluids, blood transfusion, and dialysis if required. Antibiotics are not recommended, despite the preceding diarrhoeal illness in many patients. The indications for plasma exchange in HUS are complicated, and as a general rule, plasma exchange is reserved for severe cases of HUS not associated with diarrhoea. Eculizumab, a C5 inhibitor monoclonal antibody, has shown greater efficiency than plasma exchange alone in the treatment of adult atypical HUS.

In summary, HUS is a serious condition that primarily affects young children and is characterized by a triad of symptoms. The most common cause of HUS in children is STEC 0157:H7, and diagnosis may involve various tests. Treatment is supportive, and antibiotics are not recommended. The indications for plasma exchange are complicated, and eculizumab may be more effective in treating adult atypical HUS.

The suggested decrease in blood pressure is within the kidney’s autoregulatory range for blood supply, so the GFR will remain unaffected.

The Loop of Henle and its Role in Renal Physiology

The Loop of Henle is a crucial component of the renal system, located in the juxtamedullary nephrons and running deep into the medulla. Approximately 60 litres of water containing 9000 mmol sodium enters the descending limb of the loop of Henle in 24 hours. The osmolarity of fluid changes and is greatest at the tip of the papilla. The thin ascending limb is impermeable to water, but highly permeable to sodium and chloride ions. This loss means that at the beginning of the thick ascending limb the fluid is hypo osmotic compared with adjacent interstitial fluid. In the thick ascending limb, the reabsorption of sodium and chloride ions occurs by both facilitated and passive diffusion pathways. The loops of Henle are co-located with vasa recta, which have similar solute compositions to the surrounding extracellular fluid, preventing the diffusion and subsequent removal of this hypertonic fluid. The energy-dependent reabsorption of sodium and chloride in the thick ascending limb helps to maintain this osmotic gradient. Overall, the Loop of Henle plays a crucial role in regulating the concentration of solutes in the renal system.

During the patient’s regular follow-up for diabetes and hypertension management, it was noted that both conditions increase the risk of cardiovascular complications and other related complications such as kidney and eye problems. To manage hypertension, the patient was prescribed metoprolol, a beta-blocker that reduces blood pressure by decreasing heart rate and cardiac output. Additionally, metoprolol blocks beta-1 adrenergic receptors in the juxtaglomerular apparatus of the kidneys, leading to a decrease in renin secretion. Renin is responsible for converting angiotensinogen to angiotensin I, which is further converted to angiotensin II, a hormone that increases blood pressure through vasoconstriction and sodium retention. By blocking renin secretion, metoprolol causes a decrease in blood pressure. Other antihypertensive medications work through different mechanisms, such as calcium channel blockers that dilate arterioles, ACE inhibitors that decrease angiotensin II secretion, and beta-blockers that decrease renin secretion.

The renin-angiotensin-aldosterone system is a complex system that regulates blood pressure and fluid balance in the body. The adrenal cortex is divided into three zones, each producing different hormones. The zona glomerulosa produces mineralocorticoids, mainly aldosterone, which helps regulate sodium and potassium levels in the body. Renin is an enzyme released by the renal juxtaglomerular cells in response to reduced renal perfusion, hyponatremia, and sympathetic nerve stimulation. It hydrolyses angiotensinogen to form angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme in the lungs. Angiotensin II has various actions, including causing vasoconstriction, stimulating thirst, and increasing proximal tubule Na+/H+ activity. It also stimulates aldosterone and ADH release, which causes retention of Na+ in exchange for K+/H+ in the distal tubule.

The patient’s symptoms suggest a phaeochromocytoma, which is caused by a tumor in the adrenal medulla that leads to the release of excess epinephrine. This results in refractory hypertension and severe episodes of sweating, palpitations, and anxiety.

While the pituitary gland produces hormones like thyroid-stimulating hormone and adrenocorticotropic hormone, these hormones do not directly cause the symptoms seen in this patient. Additionally, excess ACTH production is associated with Cushing’s syndrome, which does not fit the clinical picture.

The adrenal cortex has three distinct zones, each responsible for producing different hormones. The zona fasciculata produces glucocorticoids like cortisol, which can lead to Cushing’s syndrome. The zona glomerulosa produces mineralocorticoids like aldosterone, which can cause uncontrolled hypertension and electrolyte imbalances. The zona reticularis produces androgens like testosterone. However, none of these conditions match the symptoms seen in this patient.

The renin-angiotensin-aldosterone system is a complex system that regulates blood pressure and fluid balance in the body. The adrenal cortex is divided into three zones, each producing different hormones. The zona glomerulosa produces mineralocorticoids, mainly aldosterone, which helps regulate sodium and potassium levels in the body. Renin is an enzyme released by the renal juxtaglomerular cells in response to reduced renal perfusion, hyponatremia, and sympathetic nerve stimulation. It hydrolyses angiotensinogen to form angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme in the lungs. Angiotensin II has various actions, including causing vasoconstriction, stimulating thirst, and increasing proximal tubule Na+/H+ activity. It also stimulates aldosterone and ADH release, which causes retention of Na+ in exchange for K+/H+ in the distal tubule.

A Wilms’ tumour is the most prevalent type of renal carcinoma in children, making renal cell carcinoma an incorrect diagnosis. Ulcerative colitis is rare in children of this age, and the other potential diagnoses are unlikely based on the child’s symptoms.

Wilms’ Tumour: A Common Childhood Malignancy

Wilms’ tumour, also known as nephroblastoma, is a prevalent type of cancer in children, with a median age of diagnosis at 3 years old. It is often associated with Beckwith-Wiedemann syndrome, hemihypertrophy, and a loss-of-function mutation in the WT1 gene on chromosome 11. The most common presenting feature is an abdominal mass, which is usually painless, but other symptoms such as haematuria, flank pain, anorexia, and fever may also occur. In 95% of cases, the tumour is unilateral, and metastases are found in 20% of patients, most commonly in the lungs.

If a child presents with an unexplained enlarged abdominal mass, it is crucial to arrange a paediatric review within 48 hours to rule out Wilms’ tumour. The management of this cancer typically involves nephrectomy, chemotherapy, and radiotherapy if the disease is advanced. Fortunately, the prognosis for Wilms’ tumour is good, with an 80% cure rate.

Histologically, Wilms’ tumour is characterized by epithelial tubules, areas of necrosis, immature glomerular structures, stroma with spindle cells, and small cell blastomatous tissues resembling the metanephric blastema. Overall, early detection and prompt treatment are essential for a successful outcome in children with Wilms’ tumour.

The vesicouterine plexus is responsible for draining the bladder in females.

Bladder Anatomy and Innervation

The bladder is a three-sided pyramid-shaped organ located in the pelvic cavity. Its apex points towards the symphysis pubis, while the base lies anterior to the rectum or vagina. The bladder’s inferior aspect is retroperitoneal, while the superior aspect is covered by peritoneum. The trigone, the least mobile part of the bladder, contains the ureteric orifices and internal urethral orifice. The bladder’s blood supply comes from the superior and inferior vesical arteries, while venous drainage occurs through the vesicoprostatic or vesicouterine venous plexus. Lymphatic drainage occurs mainly to the external iliac and internal iliac nodes, with the obturator nodes also playing a role. The bladder is innervated by parasympathetic nerve fibers from the pelvic splanchnic nerves and sympathetic nerve fibers from L1 and L2 via the hypogastric nerve plexuses. The parasympathetic fibers cause detrusor muscle contraction, while the sympathetic fibers innervate the trigone muscle. The external urethral sphincter is under conscious control, and voiding occurs when the rate of neuronal firing to the detrusor muscle increases.

The boy’s symptoms are typical of nephrotic syndrome, which is characterized by a triad of proteinuria, hypoalbuminaemia, and oedema. Oedema is usually seen in the lower limbs, and proteinuria may cause frothy urine. Minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy are examples of nephrotic syndrome. Minimal change disease is a common cause of nephrotic syndrome, and it is characterized by effacement of the podocyte foot processes, which increases the permeability of the glomerular basement membrane and causes proteinuria.

It is important to differentiate nephrotic syndrome from nephritic syndrome, which is characterized by the presence of protein and blood in the urine. Nephritic syndrome typically presents with haematuria, oliguria, and hypertension. Alport syndrome is not a correct answer as it causes nephritic syndrome, and it is a genetic condition that affects kidney function, hearing, and vision. IgA nephropathy is also an incorrect answer as it causes nephritic syndrome and is typically associated with upper respiratory tract infections. A careful history is required to distinguish it from post-streptococcal glomerulonephritis, another cause of nephritic syndrome that occurs after a streptococcal infection.

Understanding Nephrotic Syndrome and its Presentation

Nephrotic syndrome is a condition characterized by a triad of symptoms, namely proteinuria, hypoalbuminaemia, and oedema. Proteinuria refers to the presence of excessive protein in the urine, typically exceeding 3g in a 24-hour period. Hypoalbuminaemia is a condition where the levels of albumin in the blood fall below 30g/L. Oedema, on the other hand, is the accumulation of fluid in the body tissues, leading to swelling.

Nephrotic syndrome is associated with the loss of antithrombin-III, proteins C and S, and an increase in fibrinogen levels, which increases the risk of thrombosis. Additionally, the loss of thyroxine-binding globulin leads to a decrease in total thyroxine levels, although free thyroxine levels remain unaffected.

The diagram below illustrates the different types of glomerulonephritides and how they typically present. Understanding the presentation of nephrotic syndrome and its associated risks is crucial in the diagnosis and management of this condition.

[Insert diagram here]

Overall, nephrotic syndrome is a complex condition that requires careful management to prevent complications. By understanding its presentation and associated risks, healthcare professionals can provide appropriate treatment and support to patients with this condition.

The trigone of the bladder is a sensitive area located at the base of the bladder, which is formed by the two ureteric orifices and the internal urethral orifice. This area plays a crucial role in sending signals to the brain for micturition as the bladder fills. When managing ureteric stones conservatively, the stone must pass through the ureteric and urethral orifice to be expelled from the body.

The corpus cavernosa refers to the tissue on either side of the penis that fills with blood during an erection.

The fascia-iliaca compartment is a theoretical space that contains the lateral femoral cutaneous nerve and femoral nerve. It is utilized when conducting a fascia-iliaca nerve block in a fractured neck of femur.

The inguinal canal is a structure formed by the muscles, aponeuroses, ligaments, and tendons of the anterior abdominal wall. In males, it contains blood vessels supplying the testicles and scrotum, the ductus deferens, as well as the nerves supplying these areas.

The pouch of Douglas is an anatomical area found only in women, specifically the recto-uterine area, and is not required for the passing of a ureteric stone.

Bladder Anatomy and Innervation

The bladder is a three-sided pyramid-shaped organ located in the pelvic cavity. Its apex points towards the symphysis pubis, while the base lies anterior to the rectum or vagina. The bladder’s inferior aspect is retroperitoneal, while the superior aspect is covered by peritoneum. The trigone, the least mobile part of the bladder, contains the ureteric orifices and internal urethral orifice. The bladder’s blood supply comes from the superior and inferior vesical arteries, while venous drainage occurs through the vesicoprostatic or vesicouterine venous plexus. Lymphatic drainage occurs mainly to the external iliac and internal iliac nodes, with the obturator nodes also playing a role. The bladder is innervated by parasympathetic nerve fibers from the pelvic splanchnic nerves and sympathetic nerve fibers from L1 and L2 via the hypogastric nerve plexuses. The parasympathetic fibers cause detrusor muscle contraction, while the sympathetic fibers innervate the trigone muscle. The external urethral sphincter is under conscious control, and voiding occurs when the rate of neuronal firing to the detrusor muscle increases.

The drugs that cause hyperuricaemia due to reduced urate excretion can be remembered using the mnemonic Can’t leap, which stands for Ciclosporin, Alcohol, Nicotinic acid, Thiazides, Loop diuretics, Ethambutol, Aspirin, and Pyrazinamide. Additionally, decreased tubular secretion of urate can occur in patients with acidosis, such as those with diabetic ketoacidosis, ethanol or salicylate intoxication, or starvation ketosis, as the organic acids that accumulate in these conditions compete with urate for tubular secretion.

Understanding Hyperuricaemia

Hyperuricaemia is a condition characterized by elevated levels of uric acid in the blood. This can be caused by an increase in cell turnover or a decrease in the excretion of uric acid by the kidneys. While some individuals with hyperuricaemia may not experience any symptoms, it can be associated with other health conditions such as hyperlipidaemia, hypertension, and the metabolic syndrome.

There are several factors that can contribute to the development of hyperuricaemia. Increased synthesis of uric acid can occur in conditions such as Lesch-Nyhan disease, myeloproliferative disorders, and with a diet rich in purines. On the other hand, decreased excretion of uric acid can be caused by drugs like low-dose aspirin, diuretics, and pyrazinamide, as well as pre-eclampsia, alcohol consumption, renal failure, and lead exposure.

It is important to understand the underlying causes of hyperuricaemia in order to properly manage and treat the condition. Regular monitoring of uric acid levels and addressing any contributing factors can help prevent complications such as gout and kidney stones.

The HLA system, also known as the major histocompatibility complex (MHC), is located on chromosome 6 and is responsible for human leucocyte antigens. Class 1 antigens include A, B, and C, while class 2 antigens include DP, DQ, and DR. When matching for a renal transplant, the importance of HLA antigens is ranked as DR > B > A.

Graft survival rates for renal transplants are high, with a 90% survival rate at one year and a 60% survival rate at ten years for cadaveric transplants. Living-donor transplants have even higher survival rates, with a 95% survival rate at one year and a 70% survival rate at ten years. However, postoperative problems can occur, such as acute tubular necrosis of the graft, vascular thrombosis, urine leakage, and urinary tract infections.

Hyperacute rejection can occur within minutes to hours after a transplant and is caused by pre-existing antibodies against ABO or HLA antigens. This type of rejection is an example of a type II hypersensitivity reaction and leads to widespread thrombosis of graft vessels, resulting in ischemia and necrosis of the transplanted organ. Unfortunately, there is no treatment available for hyperacute rejection, and the graft must be removed.

Acute graft failure, which occurs within six months of a transplant, is usually due to mismatched HLA and is caused by cell-mediated cytotoxic T cells. This type of failure is usually asymptomatic and is detected by a rising creatinine, pyuria, and proteinuria. Other causes of acute graft failure include cytomegalovirus infection, but it may be reversible with steroids and immunosuppressants.

Chronic graft failure, which occurs after six months of a transplant, is caused by both antibody and cell-mediated mechanisms that lead to fibrosis of the transplanted kidney, known as chronic allograft nephropathy. The recurrence of the original renal disease, such as MCGN, IgA, or FSGS, can also cause chronic graft failure.

Ramipril is the correct answer. Before starting ACE inhibitor therapy, a baseline potassium level is measured because these drugs can cause an increase in serum potassium.

Loop diuretics like furosemide can cause hypokalaemia and hyponatraemia.

Salbutamol does not lead to hyperkalaemia and can actually be used to lower serum potassium levels in emergency situations.

Taking paracetamol within recommended doses does not affect potassium levels.

Drugs and their Effects on Potassium Levels

Many commonly prescribed drugs have the potential to alter the levels of potassium in the bloodstream. Some drugs can decrease the amount of potassium in the blood, while others can increase it.

Drugs that can decrease serum potassium levels include thiazide and loop diuretics, as well as acetazolamide. On the other hand, drugs that can increase serum potassium levels include ACE inhibitors, angiotensin-2 receptor blockers, spironolactone, and potassium-sparing diuretics like amiloride and triamterene. Additionally, taking potassium supplements like Sando-K or Slow-K can also increase potassium levels in the blood.

It’s important to note that the above list does not include drugs used to temporarily decrease serum potassium levels for patients with hyperkalaemia, such as salbutamol or calcium resonium.

Overall, it’s crucial for healthcare providers to be aware of the potential effects of medications on potassium levels and to monitor patients accordingly.

The proximal convoluted tubule in the nephron is responsible for the majority of glucose reabsorption. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, acts on this area to reduce glucose reabsorption, resulting in glycosuria. While this can aid in glycaemic control and weight loss, it also increases the risk of urinary tract infections. Other SGLT-2 inhibitors include canagliflozin and empagliflozin. The distal convoluted tubule is important for ion absorption, while the cortical collecting duct regulates water reabsorption. Sulfonylureas act on pancreatic beta cells, not acinar cells, which are responsible for exocrine function and are not targeted by SGLT-2 inhibitors.

The Loop of Henle and its Role in Renal Physiology

The Loop of Henle is a crucial component of the renal system, located in the juxtamedullary nephrons and running deep into the medulla. Approximately 60 litres of water containing 9000 mmol sodium enters the descending limb of the loop of Henle in 24 hours. The osmolarity of fluid changes and is greatest at the tip of the papilla. The thin ascending limb is impermeable to water, but highly permeable to sodium and chloride ions. This loss means that at the beginning of the thick ascending limb the fluid is hypo osmotic compared with adjacent interstitial fluid. In the thick ascending limb, the reabsorption of sodium and chloride ions occurs by both facilitated and passive diffusion pathways. The loops of Henle are co-located with vasa recta, which have similar solute compositions to the surrounding extracellular fluid, preventing the diffusion and subsequent removal of this hypertonic fluid. The energy-dependent reabsorption of sodium and chloride in the thick ascending limb helps to maintain this osmotic gradient. Overall, the Loop of Henle plays a crucial role in regulating the concentration of solutes in the renal system.

The periurethral gland area of the prostate gland does not have a distinct functional or histological identity. It is composed of cells from various regions of the prostate that are linked to different medical conditions. This part of the prostate does not typically experience enlargement and lacks glandular elements. Instead, it consists solely of fibrous tissue and smooth muscle cells, as its name implies.

Benign prostatic hyperplasia (BPH) is a common condition that affects older men, with around 50% of 50-year-old men showing evidence of BPH and 30% experiencing symptoms. The risk of BPH increases with age, with around 80% of 80-year-old men having evidence of the condition. Ethnicity also plays a role, with black men having a higher risk than white or Asian men. BPH typically presents with lower urinary tract symptoms (LUTS), which can be categorised into obstructive (voiding) symptoms and irritative (storage) symptoms. Complications of BPH can include urinary tract infections, retention, and obstructive uropathy.

Assessment of BPH may involve dipstick urine testing, U&Es, and PSA testing if obstructive symptoms are present or if the patient is concerned about prostate cancer. A urinary frequency-volume chart and the International Prostate Symptom Score (IPSS) can also be used to assess the severity of LUTS and their impact on quality of life. Management options for BPH include watchful waiting, alpha-1 antagonists, 5 alpha-reductase inhibitors, combination therapy, and surgery. Alpha-1 antagonists are considered first-line for moderate-to-severe voiding symptoms and can improve symptoms in around 70% of men, but may cause adverse effects such as dizziness and dry mouth. 5 alpha-reductase inhibitors may slow disease progression and reduce prostate volume, but can cause adverse effects such as erectile dysfunction and reduced libido. Combination therapy may be used for bothersome moderate-to-severe voiding symptoms and prostatic enlargement. Antimuscarinic drugs may be tried for persistent storage symptoms. Surgery, such as transurethral resection of the prostate (TURP), may also be an option.

Fluid Therapy Guidelines for Junior Doctors

Fluid therapy is a common task for junior doctors, and it is important to follow guidelines to ensure patients receive the appropriate amount of fluids. The 2013 NICE guidelines recommend 25-30 ml/kg/day of water, 1 mmol/kg/day of potassium, sodium, and chloride, and 50-100 g/day of glucose for maintenance fluids. For the first 24 hours, NICE recommends using sodium chloride 0.18% in 4% glucose with 27 mmol/l potassium. However, the amount of fluid required may vary depending on the patient’s medical history. For example, a post-op patient with significant fluid loss will require more fluid, while a patient with heart failure should receive less fluid to avoid pulmonary edema.

It is important to consider the electrolyte concentrations of plasma and the most commonly used fluids when prescribing intravenous fluids. 0.9% saline can lead to hyperchloraemic metabolic acidosis if large volumes are used. Hartmann’s solution contains potassium and should not be used in patients with hyperkalemia. By following these guidelines and considering individual patient needs, junior doctors can ensure safe and effective fluid therapy.

Potter sequence is a condition characterized by oligohydramnios, which can be caused by renal diseases like bilateral renal agenesis, ARPKD, and ADPKD. This condition often leads to pulmonary hypoplasia, clubbed feet, and cranial anomalies in neonates. However, oesophageal atresia, which causes polyhydramnios, is not associated with Potter sequence.

Understanding Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal recessive polycystic kidney disease (ARPKD) is a rare genetic disorder that affects the kidneys and liver. Unlike the more common autosomal dominant polycystic kidney disease (ADPKD), ARPKD is caused by a defect in a gene on chromosome 6 that encodes fibrocystin, a protein essential for normal renal tubule development.

ARPKD is typically diagnosed during prenatal ultrasound or in early infancy when abdominal masses and renal failure are observed. Newborns with ARPKD may also exhibit features consistent with Potter’s syndrome due to oligohydramnios. The disease progresses rapidly, and end-stage renal failure usually develops in childhood. In addition to kidney involvement, patients with ARPKD often have liver complications such as portal and interlobular fibrosis.

Renal biopsy is a common diagnostic tool for ARPKD, which typically shows multiple cylindrical lesions at right angles to the cortical surface. Early diagnosis and management are crucial in improving outcomes for patients with ARPKD.

Renal Complications in Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) can lead to severe renal complications, including lupus nephritis, which can result in end-stage renal disease. Regular check-ups with urinalysis are necessary to detect proteinuria in SLE patients. The WHO classification system categorizes lupus nephritis into six classes, with class IV being the most common and severe form. Renal biopsy shows characteristic findings such as endothelial and mesangial proliferation, a wire-loop appearance, and subendothelial immune complex deposits.

Management of lupus nephritis involves treating hypertension and using glucocorticoids with either mycophenolate or cyclophosphamide for initial therapy in cases of focal (class III) or diffuse (class IV) lupus nephritis. Mycophenolate is generally preferred over azathioprine for subsequent therapy to decrease the risk of developing end-stage renal disease. Early detection and proper management of renal complications in SLE patients are crucial to prevent irreversible damage to the kidneys.

Spironolactone is a diuretic that acts as an aldosterone antagonist on the cortical collecting ducts. It is the first-line treatment for controlling ascites in this gentleman as it blocks the secondary hyperaldosteronism underlying the condition. The main site of action for spironolactone’s diuretic effects is the cortical collecting duct.

Spironolactone is a medication that works as an aldosterone antagonist in the cortical collecting duct. It is used to treat various conditions such as ascites, hypertension, heart failure, nephrotic syndrome, and Conn’s syndrome. In patients with cirrhosis, spironolactone is often prescribed in relatively large doses of 100 or 200 mg to counteract secondary hyperaldosteronism. It is also used as a NICE ‘step 4’ treatment for hypertension. In addition, spironolactone has been shown to reduce all-cause mortality in patients with NYHA III + IV heart failure who are already taking an ACE inhibitor, according to the RALES study.

However, spironolactone can cause adverse effects such as hyperkalaemia and gynaecomastia, although the latter is less common with eplerenone. It is important to monitor potassium levels in patients taking spironolactone to prevent hyperkalaemia, which can lead to serious complications such as cardiac arrhythmias. Overall, spironolactone is a useful medication for treating various conditions, but its potential adverse effects should be carefully considered and monitored.

The risk of urinary tract infection is higher in individuals with posterior urethral valves.

Posterior urethral valves are a frequent cause of blockage in the lower urinary tract in males. They can be detected during prenatal ultrasound screenings. Due to the high pressure required for bladder emptying during fetal development, the child may experience damage to the renal parenchyma, resulting in renal impairment in 70% of boys upon diagnosis. Treatment involves the use of a bladder catheter, and endoscopic valvotomy is the preferred definitive treatment. Cystoscopic and renal follow-up is necessary.

Before administering contrast medium, it is important to assess renal function by checking the patient’s urea and electrolytes (U&Es) due to the nephrotoxic nature of the contrast medium.

Although cardiac enzymes can be useful in ruling out myocardial infarction, they are not relevant to the administration of contrast medium in this particular clinical scenario where an acute myocardial infarction is not suspected.

While a full blood count may be part of the patient’s regular workup, it is not necessary for assessing the administration of contrast medium.

Liver function does not need to be checked prior to administering contrast medium as it is not known to be hepatotoxic.

Although contrast medium can affect thyroid function in some patients due to its iodine content, it is not routinely checked before administration.

Contrast media nephrotoxicity is characterized by a 25% increase in creatinine levels within three days of receiving intravascular contrast media. This condition typically occurs between two to five days after administration and is more likely to affect patients with pre-existing renal impairment, dehydration, cardiac failure, or those taking nephrotoxic drugs like NSAIDs. Procedures that may cause contrast-induced nephropathy include CT scans with contrast and coronary angiography or percutaneous coronary intervention (PCI). Around 5% of patients who undergo PCI experience a temporary increase in plasma creatinine levels of more than 88 µmol/L.

To prevent contrast-induced nephropathy, intravenous 0.9% sodium chloride should be administered at a rate of 1 mL/kg/hour for 12 hours before and after the procedure. Isotonic sodium bicarbonate may also be used. While N-acetylcysteine was previously used, recent evidence suggests it is not effective. Patients at high risk for contrast-induced nephropathy should have metformin withheld for at least 48 hours and until their renal function returns to normal to avoid the risk of lactic acidosis.

Bicalutamide is a medication that blocks the androgen receptor and is commonly used to treat prostate cancer. Abiraterone, on the other hand, is an androgen synthesis inhibitor that is prescribed to patients with metastatic prostate cancer who have not responded to androgen deprivation therapy. GnRH agonists like goserelin can also be used to treat prostate cancer by reducing the release of gonadotrophins and inhibiting androgen production. While cyproterone acetate is a steroidal anti-androgen, it is not as commonly used as non-steroidal anti-androgens like bicalutamide.

Prostate cancer management varies depending on the stage of the disease and the patient’s life expectancy and preferences. For localized prostate cancer (T1/T2), treatment options include active monitoring, watchful waiting, radical prostatectomy, and radiotherapy (external beam and brachytherapy). For localized advanced prostate cancer (T3/T4), options include hormonal therapy, radical prostatectomy, and radiotherapy. Patients may develop proctitis and are at increased risk of bladder, colon, and rectal cancer following radiotherapy for prostate cancer.

In cases of metastatic prostate cancer, reducing androgen levels is a key aim of treatment. A combination of approaches is often used, including anti-androgen therapy, synthetic GnRH agonist or antagonists, bicalutamide, cyproterone acetate, abiraterone, and bilateral orchidectomy. GnRH agonists, such as Goserelin (Zoladex), initially cause a rise in testosterone levels before falling to castration levels. To prevent a rise in testosterone, anti-androgens are often used to cover the initial therapy. GnRH antagonists, such as degarelix, are being evaluated to suppress testosterone while avoiding the flare phenomenon. Chemotherapy with docetaxel is also an option for the treatment of hormone-relapsed metastatic prostate cancer in patients who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated.